UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 458

Sortiert nach

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Annals of oncology, 2020-03, Vol.31 (3), p.369-376

2020

Volltextzugriff (PDF)

Impact of tumour volume on the potential efficacy of therapeutic vaccines

Current oncology (Toronto), 2011-06, Vol.18 (3), p.e150-157

2011

Volltextzugriff (PDF)

Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy

Prostate cancer and prostatic diseases, 2012-09, Vol.15 (3), p.289-295

2012

Volltextzugriff (PDF)

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

Journal of clinical oncology, 2004-07, Vol.22 (13), p.2532-2539

2004

Volltextzugriff (PDF)

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A72-A73

2019

Volltextzugriff (PDF)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.258-267

2023

Volltextzugriff (PDF)

Costimulatory molecules as adjuvants for immunotherapy

Frontiers in bioscience, 2006-01, Vol.11, p.788

2006

Volltextzugriff (PDF)

STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset

European journal of cancer (1990), 2022-10, Vol.174, p.S5-S5

2022

Volltextzugriff (PDF)

Avelumab for the treatment of metastatic Merkel cell carcinoma

Drugs of today (Barcelona, Spain : 1998), 2017-07, Vol.53 (7), p.377-383

2017

Volltextzugriff (PDF)

Androgen deprivation therapy for prostate cancer

JAMA : the journal of the American Medical Association, 2005-07, Vol.294 (2), p.238

2005

Volltextzugriff (PDF)

(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment

JNCI : Journal of the National Cancer Institute, 2015-01, Vol.107 (1), p.347-dju347

2015

Volltextzugriff (PDF)

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

Frontiers in bioscience, 2007-09, Vol.12, p.4957

2007

Volltextzugriff (PDF)

Role of vaccine therapy in cancer: biology and practice

Current oncology (Toronto), 2007-12, Vol.14 (6), p.238-245

2007

Volltextzugriff (PDF)

Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation

Developments in biologicals, 2004, Vol.116, p.27

2004

Volltextzugriff (PDF)

Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Annals of oncology, 2020-02, Vol.31 (3), p.369-376

2020

Volltextzugriff (PDF)

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

JNCI : Journal of the National Cancer Institute, 2012-07, Vol.104 (14), p.1106; author reply 1109-1106

2012

Volltextzugriff (PDF)

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Clinical cancer research, 2006-02, Vol.12 (4), p.1260-1269

2006

Volltextzugriff (PDF)

Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

Clinical cancer research, 2005-05, Vol.11 (9), p.3353-3362

2005

Volltextzugriff (PDF)

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

Journal of clinical oncology, 2005-02, Vol.23 (4), p.720-731

2005

Volltextzugriff (PDF)

Phase I JAVELIN solid tumor trial of avelumab (MSB0010718C), an anti-PD-L1 antibody: Safety and pharmacokinetics

Annals of oncology, 2015-11, Vol.26, p.viii1-viii1

2015

Volltextzugriff (PDF)

Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient

Urology (Ridgewood, N.J.), 2003-12, Vol.62, p.147-154

2003

Volltextzugriff (PDF)

A Phase I Study of Oral CC-5013(Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

Clinical genitourinary cancer, 2004-03, Vol.2 (4), p.241-243

2004

Volltextzugriff (PDF)

Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer

BJU international, 2013-06, Vol.111 (8), p.1269-1280

2013

Volltextzugriff (PDF)

Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

Cancer investigation, 2009-02, Vol.27 (2), p.221-226

2009

Volltextzugriff (PDF)

1 – 25 von 458

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(419)
Mit Volltextzugriff
(414)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Impact of tumour volume on the potential efficacy of therapeutic vaccines

Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Costimulatory molecules as adjuvants for immunotherapy

STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset

Avelumab for the treatment of metastatic Merkel cell carcinoma

Androgen deprivation therapy for prostate cancer

(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

Role of vaccine therapy in cancer: biology and practice

Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation

Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

Phase I JAVELIN solid tumor trial of avelumab (MSB0010718C), an anti-PD-L1 antibody: Safety and pharmacokinetics

Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient

A Phase I Study of Oral CC-5013(Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer

Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays

Suchergebnisse filtern